Search Results - "Weinstock, David M"

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry by Pastore, Alessandro, Jurinovic, Vindi, Kridel, Robert, Hoster, Eva, Staiger, Annette M, Szczepanowski, Monika, Pott, Christiane, Kopp, Nadja, Murakami, Mark, Horn, Heike, Leich, Ellen, Moccia, Alden A, Mottok, Anja, Sunkavalli, Ashwini, Van Hummelen, Paul, Ducar, Matthew, Ennishi, Daisuke, Shulha, Hennady P, Hother, Christoffer, Connors, Joseph M, Sehn, Laurie H, Dreyling, Martin, Neuberg, Donna, Möller, Peter, Feller, Alfred C, Hansmann, Martin L, Stein, Harald, Rosenwald, Andreas, Ott, German, Klapper, Wolfram, Unterhalt, Michael, Hiddemann, Wolfgang, Gascoyne, Randy D, Weinstock, David M, Weigert, Oliver

“…Follicular lymphoma is a clinically and genetically heterogeneous disease, but the prognostic value of somatic mutations has not been systematically assessed…”
Get full text

Bruton tyrosine kinase degradation as a therapeutic strategy for cancer by Dobrovolsky, Dennis, Wang, Eric S, Morrow, Sara, Leahy, Catharine, Faust, Tyler, Nowak, Radosław P, Donovan, Katherine A, Yang, Guang, Li, Zhengnian, Fischer, Eric S, Treon, Steven P, Weinstock, David M, Gray, Nathanael S

“…The covalent Bruton tyrosine kinase (BTK) inhibitor ibrutinib is highly efficacious against multiple B-cell malignancies. However, it is not selective for BTK,…”
Get more information

Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia by Bhatt, Shruti, Pioso, Marissa S, Olesinski, Elyse Anne, Yilma, Binyam, Ryan, Jeremy A, Mashaka, Thelma, Leutz, Buon, Adamia, Sophia, Zhu, Haoling, Kuang, Yanan, Mogili, Abhishek, Louissaint, Jr, Abner, Bohl, Stephan R, Kim, Annette S, Mehta, Anita K, Sanghavi, Sneha, Wang, Youzhen, Morris, Erick, Halilovic, Ensar, Paweletz, Cloud P, Weinstock, David M, Garcia, Jacqueline S, Letai, Anthony

“…Acquired resistance to BH3 mimetic antagonists of BCL-2 and MCL-1 is an important clinical problem. Using acute myelogenous leukemia (AML) patient-derived…”
Get more information

The promises and challenges of using gene mutations for patient stratification in follicular lymphoma by Weigert, Oliver, Weinstock, David M

“…Follicular lymphoma (FL) is a clinically and molecularly highly heterogeneous disease. Most patients achieve long-lasting remissions and have excellent overall…”
Get full text

High-throughput measurement of single-cell growth rates using serial microfluidic mass sensor arrays by Cermak, Nathan, Olcum, Selim, Delgado, Francisco Feijó, Wasserman, Steven C, Payer, Kristofor R, A Murakami, Mark, Knudsen, Scott M, Kimmerling, Robert J, Stevens, Mark M, Kikuchi, Yuki, Sandikci, Arzu, Ogawa, Masaaki, Agache, Vincent, Baléras, François, Weinstock, David M, Manalis, Scott R

“…Heterogeneity in growth phenotypes and drug susceptibility in bacterial and mammalian cells are assayed at the single-cell level using multiplexed resonant…”
Get full text

BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia by Ott, Christopher J, Kopp, Nadja, Bird, Liat, Paranal, Ronald M, Qi, Jun, Bowman, Teresa, Rodig, Scott J, Kung, Andrew L, Bradner, James E, Weinstock, David M

“…We investigated the therapeutic potential of JQ1, an inhibitor of the BET class of human bromodomain proteins, in B-cell acute lymphoblastic leukemia (B-ALL)…”
Get more information

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy by Jurinovic, Vindi, Kridel, Robert, Staiger, Annette M, Szczepanowski, Monika, Horn, Heike, Dreyling, Martin H, Rosenwald, Andreas, Ott, German, Klapper, Wolfram, Zelenetz, Andrew D, Barr, Paul M, Friedberg, Jonathan W, Ansell, Stephen, Sehn, Laurie H, Connors, Joseph M, Gascoyne, Randy D, Hiddemann, Wolfgang, Unterhalt, Michael, Weinstock, David M, Weigert, Oliver

“…Follicular lymphoma (FL) is a clinically and molecularly heterogeneous disease. Posttreatment surrogate end points, such as progression of disease within 24…”
Get more information

DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance by Togami, Katsuhiro, Pastika, Timothy, Stephansky, Jason, Ghandi, Mahmoud, Christie, Amanda L., Jones, Kristen L., Johnson, Carl A., Lindsay, Ross W., Brooks, Christopher L., Letai, Anthony, Craig, Jeffrey W., Pozdnyakova, Olga, Weinstock, David M., Montero, Joan, Aster, Jon C., Johannessen, Cory M., Lane, Andrew A.

“…The interleukin-3 receptor α subunit, CD123, is expressed in many hematologic malignancies including acute myeloid leukemia (AML) and blastic plasmacytoid…”
Get full text

miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors by Moskwa, Patryk, Buffa, Francesca M, Pan, Yunfeng, Panchakshari, Rohit, Gottipati, Ponnari, Muschel, Ruth J, Beech, John, Kulshrestha, Ritu, Abdelmohsen, Kotb, Weinstock, David M, Gorospe, Myriam, Harris, Adrian L, Helleday, Thomas, Chowdhury, Dipanjan

“…Expression of BRCA1 is commonly decreased in sporadic breast tumors, and this correlates with poor prognosis of breast cancer patients. Here we show that BRCA1…”
Get more information

Inhibition of USP10 induces degradation of oncogenic FLT3 by Weisberg, Ellen L, Schauer, Nathan J, Yang, Jing, Lamberto, Ilaria, Doherty, Laura, Bhatt, Shruti, Nonami, Atsushi, Meng, Chengcheng, Letai, Anthony, Wright, Renee, Tiv, Hong, Gokhale, Prafulla C, Ritorto, Maria Stella, De Cesare, Virginia, Trost, Matthias, Christodoulou, Alexandra, Christie, Amanda, Weinstock, David M, Adamia, Sophia, Stone, Richard, Chauhan, Dharminder, Anderson, Kenneth C, Seo, Hyuk-Soo, Dhe-Paganon, Sirano, Sattler, Martin, Gray, Nathanael S, Griffin, James D, Buhrlage, Sara J

“…An inhibitor of the deubiquitinase (DUB) USP10 regulates the degradation of oncogenic FLT3, thus defining USP10 as a DUB for FLT3 and providing a therapeutic…”
Get full text

Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer by Choi, Young Eun, Meghani, Khyati, Brault, Marie-Eve, Leclerc, Lucas, He, Yizhou J., Day, Tovah A., Elias, Kevin M., Drapkin, Ronny, Weinstock, David M., Dao, Fanny, Shih, Karin K., Matulonis, Ursula, Levine, Douglas A., Konstantinopoulos, Panagiotis A., Chowdhury, Dipanjan

“…High-grade serous ovarian carcinomas (HGSOCs) with BRCA1/2 mutations exhibit improved outcome and sensitivity to double-strand DNA break (DSB)-inducing agents…”
Get full text

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas by He, Yonghan, Koch, Raphael, Budamagunta, Vivekananda, Zhang, Peiyi, Zhang, Xuan, Khan, Sajid, Thummuri, Dinesh, Ortiz, Yuma T., Zhang, Xin, Lv, Dongwen, Wiegand, Janet S., Li, Wen, Palmer, Adam C., Zheng, Guangrong, Weinstock, David M., Zhou, Daohong

“…Background Patients with advanced T cell lymphomas (TCLs) have limited therapeutic options and poor outcomes in part because their TCLs evade apoptosis through…”
Get full text

Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions by Yoshida, Noriaki, Shigemori, Kay, Donaldson, Nicholas, Trevisani, Christopher, Cordero, Nicolas A, Stevenson, Kristen E, Bu, Xia, Arakawa, Fumiko, Takeuchi, Mai, Ohshima, Koichi, Yoda, Akinori, Ng, Samuel Y, Weinstock, David M

“…Adult T-cell leukemia/lymphoma (ATLL) in Japan presents at a median age of 70 years and only 5% of patients are <50 years of age. We conducted RNA and targeted…”
Get more information

Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate by Stevens, Mark M, Maire, Cecile L, Chou, Nigel, Murakami, Mark A, Knoff, David S, Kikuchi, Yuki, Kimmerling, Robert J, Liu, Huiyun, Haidar, Samer, Calistri, Nicholas L, Cermak, Nathan, Olcum, Selim, Cordero, Nicolas A, Idbaih, Ahmed, Wen, Patrick Y, Weinstock, David M, Ligon, Keith L, Manalis, Scott R

“…The efficacy of cancer drugs is profiled by measuring changes in the mass of single tumor cells. Assays that can determine the response of tumor cells to…”
Get full text

Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia by Sujobert, Pierre, Poulain, Laury, Paubelle, Etienne, Zylbersztejn, Florence, Grenier, Adrien, Lambert, Mireille, Townsend, Elizabeth C., Brusq, Jean-Marie, Nicodeme, Edwige, Decrooqc, Justine, Nepstad, Ina, Green, Alexa S., Mondesir, Johanna, Hospital, Marie-Anne, Jacque, Nathalie, Christodoulou, Alexandra, Desouza, Tiffany A., Hermine, Olivier, Foretz, Marc, Viollet, Benoit, Lacombe, Catherine, Mayeux, Patrick, Weinstock, David M., Moura, Ivan C., Bouscary, Didier, Tamburini, Jerome

“…AMPK is a master regulator of cellular metabolism that exerts either oncogenic or tumor suppressor activity depending on context. Here, we report that the…”
Get full text

The evolution of influenza resistance and treatment by Weinstock, David M, Zuccotti, Gianna

Get more information

Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations by Ajore, Ram, Raiser, David, McConkey, Marie, Jöud, Magnus, Boidol, Bernd, Mar, Brenton, Saksena, Gordon, Weinstock, David M, Armstrong, Scott, Ellis, Steven R, Ebert, Benjamin L, Nilsson, Björn

“…Heterozygous inactivating mutations in ribosomal protein genes (RPGs) are associated with hematopoietic and developmental abnormalities, activation of p53, and…”
Get full text

Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype by Kim, Jung Min, Parmar, Kalindi, Huang, Min, Weinstock, David M, Ruit, Carrie Ann, Kutok, Jeffrey L, D'Andrea, Alan D

“…Fanconi anemia (FA) is a human genetic disease characterized by chromosome instability, cancer predisposition, and cellular hypersensitivity to DNA…”
Get more information

Chromosomal translocations induced at specified loci in human stem cells by Brunet, Erika, Simsek, Deniz, Tomishima, Mark, DeKelver, Russell, Choi, Vivian M, Gregory, Philip, Urnov, Fyodor, Weinstock, David M, Jasin, Maria

“…The precise genetic manipulation of stem and precursor cells offers extraordinary potential for the analysis, prevention, and treatment of human malignancies…”
Get more information

New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation by Arwood, Matthew L, Liu, Yao, Harkins, Shannon K, Weinstock, David M, Yang, Lei, Stevenson, Kristen E, Plana, Olivia D, Dong, Jingyun, Cirka, Haley, Jones, Kristen L, Virtanen, Anniina T, Gupta, Dikshat G, Ceas, Amanda, Lawney, Brian, Yoda, Akinori, Leahy, Catharine, Hao, Mingfeng, He, Zhixiang, Choi, Hwan Geun, Wang, Yaning, Silvennoinen, Olli, Hubbard, Stevan R, Zhang, Tinghu, Gray, Nathanael S, Li, Loretta S

“…Recurrent JAK2 alterations are observed in myeloproliferative neoplasms, B-cell acute lymphoblastic leukemia, and other hematologic malignancies. Currently…”
Get more information